Antibiotic-resistant Mycobacterium tuberculosis strains are jeopardizing efforts in eradicating the global Tuberculosis crisis. Mycobacterium tuberculosis is inherently resistant to many antibiotics limiting the number of compounds accessible for therapy. This inherent resistance is caused by several mechanisms.
A key goal of our drug discovery research is tackling antimicrobial resistance through the identification of bioactive compounds from plants that have the potential to become therapeutic agents in the treatment of tuberculosis. Our team leverages core expertise in assay development, high-throughput screening, hit-to-lead medicinal chemistry and in vivo pharmacology to expedite the drug discovery process.
Developing novel antibacterial agents and studying mechanisms of resistance to combat tuberculosis and other drug-resistant bacterial infections.
Exploring medicinal plants and natural compounds to discover new drugs that can address emerging global health threats, particularly antimicrobial resistance.
Investigating the safety, efficacy, and biological activity of natural and synthetic compounds using advanced pharmacological models and high-throughput screening assays.
Advancing research on infectious diseases such as respiratory infections and promoting responsible antimicrobial use within healthcare systems.